What does additional paid-in capital mean?

This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.

MapLight Therapeutics, Inc. MPLT Additional Paid-In Capital

Additional Paid-In Capital at other companies

Acadia PharmaceuticalsACAD

$3.06B+3.7%

Xenon PharmaceuticalsXENE

$264.88M+27.1%

Rapport Therapeutics, Inc.RAPP

$727.05M+67.6%

Mirum Pharmaceuticals, Inc.MIRM

$1.7B+90.5%

Neurocrine BiosciencesNBIX

——

AbbVieABBV

——

Other financials

Income statement

See full

Operating income-$64.5M-174%

Net income-$60.7M-172%

EPS (diluted)-$1.34+95.4%

Balance sheet

See full

Cash & equivalents$55.7M—

Total debt$5.6M—

Total equity$399.8M+285%

Total assets$418.8M—

Cash flow

See full

Operating cash flow-$51.2M-100%

CapEx$24.0K—

Free cash flow-$51.2M—

Valuation

See full

Market cap$1.39B—

Enterprise value$1.34B—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity0×—

Current ratio22.9×—

Where this comes from

Reported directly by MapLight Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: MapLight Therapeutics, Inc. ’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MapLight Therapeutics, Inc. 's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MapLight Therapeutics, Inc. 's additional paid-in capital?: MapLight Therapeutics, Inc. (MPLT) reported additional paid-in capital of $821.9M in Q1 2026.
What does additional paid-in capital mean?: This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.